Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. by Douglas, Ian J et al.
Douglas, IJ; Langham, J; Bhaskaran, K; Brauer, R; Smeeth, L (2013)
Orlistat and the risk of acute liver injury: self controlled case series
study in UK Clinical Practice Research Datalink. BMJ (Clinical re-
search ed), 346. f1936. ISSN 0959-8138 DOI: 10.1136/bmj.f1936
Downloaded from: http://researchonline.lshtm.ac.uk/790306/
DOI: 10.1136/bmj.f1936
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Orlistat and the risk of acute liver injury: self controlled
case series study in UK Clinical Practice Research
Datalink
OPEN ACCESS
Ian J Douglas lecturer in pharmacoepidemiology, Julia Langham lecturer, Krishnan Bhaskaran
lecturer in statistical epidemiology, Ruth Brauer research student, Liam Smeeth professor of clinical
epidemiology
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
Abstract
Objective To measure the association between orlistat and acute liver
injury.
Design Self controlled case series study.
Setting Population based primary care setting, United Kingdom.
Participants 94 695 patients receiving orlistat and registered in the UK
Clinical Practice Research Datalink and linked with Hospital Episode
Statistics data between 1999 and 2011.
Main outcome measure Relative incidence of acute liver injury
comparing periods when patients were receiving orlistat with periods of
non-usage.
Results Among 94 695 patients who received orlistat, 988 cases of
acute liver injury were identified, with 335 confirmed as definite cases
and 653 as probable cases. For all cases an increased incidence of liver
injury was detected during the 90 day period before orlistat was first
started, with an incidence rate ratio of 1.50 (95% confidence interval
1.10 to 2.06). The incidence remained raised during the first 30 days of
treatment (2.21, 1.43 to 3.42), before returning to baseline levels with
prolonged treatment. When the risk during the first 90 days of treatment
was compared with the 90 days preceding first treatment, the incidence
of liver injury was not increased (1.02, 0.67 to 1.56). An analysis
restricted to definite cases showed no evidence of an increased risk of
liver injury during treatment.
Conclusion The incidence of acute liver injury was higher in the periods
both immediately before and immediately after the start of orlistat
treatment. This suggests that the observed increased risks of liver injury
linked to the start of treatment may reflect changes in health status
associated with the decision to begin treatment rather than any causal
effect of the drug.
Introduction
Orlistat (Xenical; Roche) is used in the treatment of obesity and
was approved by the European Commission in 1998. It is a
selective inhibitor of gastric and pancreatic lipase and leads to
a reduction in dietary fat lipolysis and absorption.1 Although
mild but unpleasant gastrointestinal side effects are commonly
reported with orlistat use there is also concern that it may be
associated with an increased risk of serious hepatic events. The
US Food and Drug Administration first issued a warning about
a possible link between orlistat and serious liver injury in 20092 3
based on an analysis of 32 case reports received between 1999
and 2008. The European Medicines Agency has also reviewed
the strength of evidence relating to this possible risk.4 The
analysis of individual case reports is often unable to give reliable
conclusions about causality and a range of population based
studies are needed to help inform decisions about the likely
risks and benefits of orlistat. A meta-analysis of clinical trial
data involving around 10 000 patients found no evidence that
orlistat was associated with increases in selected variables of
liver function,5 and a likely mechanism of action has not been
identified. Assessments by both agencies concluded that there
was no strong evidence to determine a causal association.
However, results from clinical trials do not always reflect the
effects of drugs when used in the general population, and to
date no studies have been published based on orlistat use in the
real world. Orlistat remains the only drug treatment option for
obesity, is widely used, and in many countries is available
without prescription. Further clarity on safety is therefore
needed.
People using orlistat are likely to have a different underlying
risk of acute liver events from non-users owing to obesity and
its comorbidities, and many study designs would be unable to
fully account for these important differences. We conducted a
self controlled case series study in which each participant acts
as his or her own control to avoid the inherent biases caused by
differences between people.
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Methods
We carried out a population based study using the UK Clinical
Practice Research Datalink (formerly the General Practice
Research Database) linked with Hospital Episode Statistics data
to provide a more formal assessment of any association between
orlistat and adverse liver events.
The Clinical Practice Research Datalink
The Clinical Practice Research Datalink contains anonymised
information on over 11 million patients registered at over 600
general practices in the United Kingdom.6 7 Information is
continuously recorded for each patient, including a record of
each consultation, diagnoses, prescribed medicines, and basic
demographic data. The geographical distribution and size of
general practices represented in Clinical Practice Research
Datalink is largely representative of the population of England
and Wales, and people registered on the database are
representative of the UK population in terms of age and sex.8
The quality of data held is subject to rigorous checks and regular
audits and the data have been used to conduct over 600 peer
reviewed published studies. The information obtained from the
database is entirely anonymised.
Hospital episode statistics
Hospital episode statistics is a database containing information
on all admissions to National Health Service hospitals in
England (including private patients treated in NHS hospitals).9
Clinical information relating to diagnoses and procedures carried
out during each hospital stay are recorded using ICD-10 codes
(international classification of diseases, 10th revision). Around
half of the active practices contributing to the Clinical Practice
Research Datalink have been linked with Hospital Episode
Statistics, thus providing additional clinical information for all
patients from these practices who were admitted to hospital
between 1997 and 2010.
Study design
We carried out a self controlled case series analysis. This study
design is derived from rate modelling using a Poisson
distribution and is comparable with cohort methodology. It
relies on within person comparisons in a population with both
the outcome and exposure of interest.10 11 Incidence rate ratios
are derived, comparing the rate of events during exposed periods
with that during all other observed periods. A major advantage
of this design is that it removes the potential confounding effect
of both recorded and unrecorded characteristics that vary
between people but are fixed over time within people. Age,
which varies over time, is adjusted for in the analysis.
The method relies on three key assumptions. Firstly, recurrent
events must be independent—that is, the likelihood of a second
event is not influenced by having a first event. Although this
may not be true for liver injury, a convenient way to avoid bias
is to consider only the first incident case of an event as a relevant
outcome, which has been shown to be a valid approach.10
Secondly, the occurrence of an event should not alter the
probability of subsequent use. For example, if the event is a
contraindication to prescribing the drug of interest, it would
lead to a low rate of events in the period leading up to the first
period of use and may artificially exaggerate the relative rate
of events occurring in exposed versus unexposed periods. This
potential bias can be overcome by removing a predefined period
of time before exposure from all other unexposed (baseline)
time.12
Thirdly, the event of interest must not censor the observation
period—for example, if the event increases the likelihood of
death—although there is some evidence that themethod is robust
to this assumption.11 Whether this assumption is fulfilled can
be readily checked by measuring short term mortality after the
event of interest.
Study participants, exposure, and outcome
Patients of all ages were selected from the population registered
with the Clinical Practice Research Datalink with an active
registration status at any point during the study period, between
1 January 1999 and 30 March 2011. We chose 1999 as the
earliest possible start date as orlistat was launched that year.
Eligible participants were patients with both the exposure of
interest (prescribed orlistat) and the outcome of interest
(idiopathic acute liver injury) during this period. To ensure that
we included only new users of orlistat, all participants had to
have at least 12 months continuous registration in the Clinical
Practice Research Datalink before the first recorded orlistat
prescription; the first 12 months of continuous registration were
excluded from all analyses. The end of observation for each
participant was the earliest of death, transfer out of the practice,
last data collection date for the practice, or the date a medical
code was recorded that excluded the patient from further
observation.Within this cohort of exposed patients, we identified
cases by a search of data in both Clinical Practice Research
Datalink and Hospital Episode Statistics, using Read codes, test
results, and ICD-10 codes.
The specific nature of any hepatic effect of orlistat has not been
established and for this reason we adopted a broad case
definition. We defined patients as cases if they had a first
recorded incident idiopathic liver event during continuous
registration, again excluding the first 12 months of continuous
registration to ensure events were incident. We defined cases
as “definite” if they had a relevant clinical code (Read codes in
the Clinical Practice Research Datalink and ICD-10 codes in
Hospital Episode Statistics) indicating a possible idiopathic
hepatic event plus evidence of abnormal liver function test
results within 30 days plus a referral to hospital within 60 days
related to a hepatic event. The incident date for the case was set
as the earliest of these events. We defined “probable” cases as
those with a relevant medical code but with only one of the
further “definite” case criteria—for example, a record of a
referral or a confirmatory liver function test result.
The definition of an abnormal liver function test result indicative
of an adverse hepatic event was either an increase of more than
twice the upper limit of normal for alanine aminotransferase
level or a combined increase in aspartate aminotransferase,
alkaline phosphatase, and total bilirubin levels, provided one
of them was twice the upper limit of normal. Because the first
adverse liver event could affect the likelihood of subsequent
events, we only used the first incident occurrence of idiopathic
acute liver injury in the analysis.10
The primary study population comprised both definite and
probable cases. The distinction between definite and probable
is to some extent driven by the severity of events, with less
severe events possibly not resulting in a secondary referral. The
analysis of the combined group therefore maximises statistical
power. We also carried out a restricted analysis among patients
who were classified as definite cases, as they had additional
evidence of liver injury.
We used recorded event terms indicating other likely causes of
the hepatic injury to exclude patients from the study population.
These were applied in three categories. Firstly, we excluded all
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patients with a history of permanent liver damage (for example,
cirrhosis) before the event date. Secondly, we excluded patients
with a record of any cancer before the event or up to 12 months
after the event. Finally, we excluded patients with a record of
other non-drug related hepatic illness or major risk for hepatic
illness (for example, viral hepatitis, non-alcoholic fatty liver,
alcoholism) up to 12 months before or after the event. For any
patients who developed one of these conditions more than 12
months after their incident case event, we censored follow-up
at the time the condition was recorded.
Orlistat use was determined using prescribing records in the
Clinical Practice Research Datalink. The expected duration of
each prescription was calculated using dosage and pack size
information where available. Where this information was
missing, we imputed the median pack duration of 28 days.
Where a gap of less than 60 days occurred between the end of
one prescription and the start of another, we considered use to
be continuous to allow for lack of adherence and drug
stockpiling.
Statistical analysis
We used conditional poisson regression to calculate incidence
rate ratios comparing the risk of liver injury during periods of
orlistat use with periods of non-use, adjusting for age in five
year bands. Figure 1⇓ shows a typical timeline for a single
patient in the study. We divided patient time into six discrete
categories; absence of orlistat, 90 days before first ever orlistat
prescription, first 30 days of orlistat use, 31-60 days of orlistat
use, 61-90 days of orlistat use, and more than 90 days of orlistat
use. We included the 90 day period before first orlistat use as
a precaution to assess whether the likelihood of starting orlistat
is temporarily affected by having a liver event. The removal of
this period from baseline time avoids biased estimates when
such a mechanism is present.10 We separated the first 90 days
of use into three 30 day periods to allow the detection of any
temporary change in the relative risk of liver events; if a causal
association with treatment exists it is possible that the risk of
hepatic events may vary with duration of use, and many adverse
drug reactions occur during the early stages of a treatment.
Additional analyses
We carried out several sensitivity and secondary analyses.
Firstly, we censored all follow-up at 1 January 2009 as orlistat
was made available without prescription during 2009 and so
ascertainment of use beyond this time may be incomplete. An
additional restricted analysis was done excluding all Hospital
Episode Statistics data, since data from this linkage were not
available for all patients. After observing an unexpected finding
in the 90 day period before first use, we did a further analysis
comparing the risk of liver events in the first 90 or 30 days of
treatment with that in the 90 or 30 days before first orlistat use.
Finally, to check the assumption that events do not lead to
censoring of the observation period, we also determined the
number of deaths within one year of the recorded liver injury.
All data analysis was carried out using Stata 12.
Results
The Clinical Practice Research Datalink contained records for
94 695 patients who had received at least one prescription for
Orlistat. Of these, 2973 patients had an eligible clinical code
indicating possible liver injury. Overall, 1985 were excluded;
998 had their index event outside the observation period and
447 had recorded events that met the exclusion criteria. A further
272 were excluded as they were found to have normal liver
function test results and 268 had no liver function test results
recorded and were not referred to secondary care. This left 988
eligible cases. Figure 2⇓ shows the exclusion and case
categorisation process.
Table 1⇓ shows the personal characteristics of the definite and
possible cases. Among the 988 definite and probable cases, the
median age at first orlistat prescription was 48 years and the
mean observation period was 9.2 years. The mean duration of
orlistat treatment was 10.8 months, and this was slightly longer
for women than for men. Ninety four patients (9.5%) had a liver
event during orlistat treatment, with the remaining 894 occurring
during periods of non-use. Age and sex patterns were similar
when restricted to the 335 definite cases, with 27 (8%)
experiencing a liver event during orlistat use.
Table 2⇓ summarises the hepatic events that identified patients
as cases. Most were coded as raised liver function test results
(85%), with a small proportion indentified through codes for
jaundice (14%), hepatitis (2%), or liver failure (<1%).
Table 3⇓ shows age adjusted incidence rate ratios for liver injury
comparing the predefined risk periods of orlistat use with periods
of non-use. For the 988 definite and probable cases the risk of
liver injury was more than doubled during the first 30 days of
treatment (incidence rate ratio 2.21, 95% confidence interval
1.43 to 3.42). This decreased to 1.06 (0.57 to 1.99) during
treatment days 31-60. The risk was not increased during
treatment days 61-90 (1.32, 0.75 to 2.34) and >90 (0.78, 0.58
to 1.05). The incidence rate ratio was also increased during the
90 day period before the first orlistat prescription (1.50, 1.10 to
2.06). This unexpected finding led us to undertake a
retrospective secondary analysis comparing the incidence of
liver injury in the 90 days before the first orlistat prescription
with the 90 day period after the first prescription. In this
analysis, we found no evidence that the risk of liver injury was
higher in the period after treatment had started than in the period
before treatment (1.02, 0.67 to 1.56). The incidence rate ratio
with the shorter period of 30 days before and after a first
prescription for orlistat was 1.11 (0.59 to 2.06).
In the analysis restricted to definite cases, an increased risk of
liver injury was seen in the 90 days before orlistat prescription
(1.75, 1.05 to 2.91). Evidence of an increased risk during any
period of orlistat use was lacking, although the number of events
in each exposure period was low. Comparing the 90 day period
after the first orlistat prescription with the 90 day period before
the prescription the incidence rate ratio was 0.63 (0.28 to 1.38),
again suggesting no evidence of an increased risk during early
use.
Sensitivity analyses censoring all follow-up at 1 January 2009
(orlistat became available without prescription in the United
Kingdom in 2009) or excluding Hospital Episode Statistics data
from the analysis made no material difference to the results. Of
note, Hospital Episode Statistics data only informed the case
status for 52 cases. Mortality within a year of the liver injury
was low, with six patients recorded as dead within 12 months
of the event. An analysis excluding these patients had no impact
on the results.
Discussion
The incidence of acute liver injury from orlistat use is
approximately doubled during a short period both before (90
days) and after the start of treatment (30 days) compared with
background incidence, suggesting that the start of treatment
tends to coincide with a period of increased risk of liver injury.
Our results were not suggestive of a causal link between orlistat
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use and liver injury: the incidence just after starting treatment
was comparable with that just before starting treatment. The
incidence of liver injury after more than 30 days use was similar
to that during the period of non-use. These results are likely to
be generalisable to other populations receiving orlistat, as the
Clinical Practice Research Datalink used in this study is
representative of the UK population.
Several factors may explain why the start of orlistat treatment
tends to coincide with times of increased risk of liver injury.
The initiation of any new drug often occurs at a time of specific
concerns about a patient’s health. For an obese patient, the
decision to start orlistat may be a response to changes in obesity
related health problems. This could include symptoms related
to underlying liver disease, which is a common complication
of obesity,13 and the investigation of such symptoms may result
in a diagnosis that would qualify a patient as a case in our study.
Even changes in health status not directly related to the liver
could result in a range of tests being performed, including liver
function tests; again the results of these could lead to the
identification of asymptomatic increases in liver function
markers sufficient to qualify the patient as a case. Consistent
with this hypothesis, we noted that the rate of liver function
testing (regardless of result) among all 94 695 patients receiving
orlistat was higher during the 90 days before and after the first
prescription for orlistat (774 tests per 1000 patient years)
compared with other periods (481 tests per 1000 patient years).
We chose to use the self controlled case series design because
participants act as their own controls, and therefore some of the
problems of confounding inherent to other study designs are
avoided. Treated and untreated patients generally differ in
important ways that can influence the outcome being studied,
and although methods to account for these differences are
routinely used in observational research, residual confounding
often remains a problem. The key assumptions underpinning
the self controlled case series were met, making it a good choice
of design for this study; the event of interest was non-recurrent
and did not lead to any substantial increase in short term
mortality. Although our results show that the event itself may
lead to a short term change in the likelihood of receiving orlistat,
this period of influence seems to be short lived and was
accounted for in our analysis by separating out a period before
orlistat use. The comparison of later usage with non-usage
periods was consistent with no change in event rate, and thus a
constant risk of liver injury during all other times. The separation
of the period before orlistat use from all other periods of non-use
also highlights a unique and important advantage of the self
controlled case series over the cohort method as it allowed us
to directly compare the risk of liver injury in the period before
orlistat use with the first period of use. In a traditional cohort
design, the pre-use period would not be included in the analysis,
and could have led to the conclusion that starting orlistat
treatment is associated with an increased risk of liver injury.
Comparison with other studies
These results need to be viewed in the context of other
information already available on this topic. Pre-marketing
randomised trials did not detect liver injury as a possible effect
of orlistat, and a recent meta-analysis including around 10 000
patients from randomised trials found no association between
orlistat and increases in either alanine aminotransferase or
bilirubin levels.5 14 However, the selective nature and limited
numbers included in clinical trials can mean important safety
findings are not identified. Formal studies of this issue based
on real world usage of orlistat have not been published to date
and the signal regarding possible liver injury is based on the
analysis of individual case reports submitted to regulatory
authorities. Although such analyses can sometimes provide
useful insight into possible causality, such conclusions are often
not possible. Indeed our study suggests one of the reasons
individual doctors may have made a link between orlistat and
adverse liver events results from a non-causal and temporary
increase in the likelihood of such events around this time.
Strengths and limitations of this study
For this study we defined the outcome by searching electronic
general practice records for evidence of liver injury. Where
available we supplemented this information with records of
hospital admissions, although most cases (95%) were identified
from general practice records only. This could be because the
severity of liver injury in these patients was generally
insufficient to warrant admission to hospital.
We graded cases as either definite or probable depending on
the evidence available, although the less severe nature of many
events is likely to mean some definite cases were incorrectly
classed as probable. The impact of such misclassification is
likely to be minimal as the results of the analysis of only definite
cases also failed to find evidence of an increased risk associated
with orlistat. The accuracy of event timing is important to ensure
events are counted during the correct usage time.While we have
taken care to assign incidence at the earliest date with evidence
of liver injury, it is possible that some events could have started
earlier. However, this is unlikely to have led to large
discrepancies in event timing, and if an event had been caused
by orlistat it would generally have been assigned to a later period
of treatment, meaning an association would still be detected.
Notably, in this study most events identified were of raised liver
function test results, with few cases of serious liver injury such
as hepatic failure or necrosis. Of the events occurring during
orlistat treatment 99% were of raised liver function test results
or jaundice, with a single case of hepatitis and no cases of liver
failure or necrosis. Serious liver events were therefore rare
during treatment with orlistat in this group of almost 100 000
patients. Although it is possible that low level asymptomatic
changes in liver functionmay have gone undetected, more severe
events would almost certainly require medical attention and
would be recorded by the general practitioner.
We defined the patients’ usage status according to date of
prescription issue, rather than precise records of drug
consumption, which are not available. It is likely that in some
instances use will have been overestimated, which could lead
to a result bias towards no effect. However, the median period
of usage was almost a year, and it is unlikely that patients
continued to obtain repeat prescriptions for a drug they were
not using.
Other possible biases related to orlistat being obtained without
prescription after 2009 or case status being ascertained
differently in patients from practices linked to Hospital Episode
Statistics were dealt with in sensitivity analyses. The results
were robust to these possible problems.
Conclusions
Obesity has become a major health problem worldwide and
orlistat is currently the only available drug intervention of
proved efficacy. Possible safety concerns about orlistat are
therefore of great importance. By using the self controlled case
series design we were able to establish that the risk of liver
injury was increased to a similar degree both just before and
just after starting treatment, strongly suggesting that the
association is non-causal. Our results imply that studies based
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only on traditional epidemiological designs or spontaneous
adverse events are likely to detect associations between starting
orlistat treatment and liver injury, but such associations should
not be interpreted as evidence for an adverse causal effect of
the drug unless an increased risk in the period immediately
before the start of treatment can be excluded.
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What is already known on this topic
Since early 2000 reports of liver injury associated with orlistat have accumulated, raising concerns about its safety
Although randomised trials found no such association, observational studies based on real world orlistat use are lacking
What this study adds
In a large population based cohort, the rate of adverse liver events seems to be temporarily increased both immediately before and
immediately after starting treatment with orlistat
This suggests that the increased risk of liver injury linked to orlistat may reflect changes in underlying health status associated with the
decision to start treatment, rather than a causal effect of the drug
Tables
Table 1| Characteristics of study population
Exposed periodUnexposed period*
Mean (SD) age at start
of orlistat (years)
No of
patientsCharacteristics
Mean (SD) duration of use
(years)No of events
Mean (SD) duration of
follow-up (years)No of events
Definite and probable
cases:
0.9 (0.9)949.2 (2.7)89448.4 (12.8)988All
0.8 (0.8)259.1 (2.8)28448.9 (11.8)309Men
0.9 (1.0)699.3 (2.7)61048.3 (13.3)679Women
Definite cases:
0.9 (0.9)279.3 (2.5)30847.9 (13.1)335All
0.8 (0.7)99.0 (2.4)8948.1 (11.1)98Men
0.9 (1.0)189.4 (2.6)21947.8 (13.9)237Women
*Before or after orlistat use.
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Table 2| Distribution of adverse liver events. Values are numbers (percentages)
TotalProbable casesDefinite casesRecorded hepatic event
836 (85)557 (85)279 (83)Raised liver function test results
136 (14)83 (13)53 (16)Jaundice
19 (2)12 (2)7 (2)Hepatitis
1 (<1)1 (<1)0Liver failure
000Liver necrosis
13 (1)8 (1)5 (1)Other*
Patients with more than one recorded hepatic event during same episode are included in all relevant categories, therefore counts cannot be summed to equal
total patients.
*Mostly procedural—for example, liver biopsy.
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Table 3| Self controlled case series analysis for orlistat use and risk of liver injury
Age adjusted rate ratio (95% CI)No of eventsPatient yearsVariables
Definite and probable cases (n=988)
Primary analyses:
—8528872Absence of orlistat
1.50 (1.10 to 2.06)4224190 days before prescription
2.21 (1.43 to 3.42)21811-30 days orlistat
1.06 (0.57 to 1.99)108031-60 days orlistat
1.32 (0.75 to 2.34)127861-90 days orlistat
0.78 (0.58 to 1.05)51986>90 days orlistat
Secondary analyses:
—4224190 days before prescription
1.02 (0.67 to 1.56)432401-90 days orlistat
—198130 days before prescription
1.11 (0.59 to 2.06)21811-30 days orlistat
Definite cases (n=335)
Primary analyses:
—2923042Absence of orlistat
1.75 (1.05 to 2.91)168290 days before prescription
0.32 (0.05 to 2.30)1271-30 days orlistat
0.97 (0.31 to 3.04)32731-60 days orlistat
2.02 (0.90 to 4.54)62661-90 days orlistat
0.72 (0.43 to 1.22)17211>90 days orlistat
Secondary analyses:
—168290 days before prescription
0.63 (0.28 to 1.38)10811-90 days orlistat
—52730 days before prescription
0.20 (0.02 to 1.71)1271-30 days orlistat
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Figures
Fig 1 Typical timeline for patient in study. *Liver injury could occur at any point during observation period
Fig 2 Flow of participants through study
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